Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients.
Front Oncol
; 13: 1125013, 2023.
Article
in En
| MEDLINE
| ID: mdl-36895480
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Front Oncol
Year:
2023
Document type:
Article
Affiliation country:
Italia
Country of publication:
Suiza